SCHEMBL16626512

SCHEMBL16626512

CNCc1cn(S(=O)(=O)c2cccc(C(F)(F)F)c2)c2cc(Nc3ccc(Cl)cc3C(F)(F)F)ccc12

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.40
RORC P51449 3/20 0.39
MPO P05164 1/20 0.38
SLC20A2 Q08357 1/20 0.37
SLC20A1 Q8WUM9 1/20 0.37
CNR2 P34972 4/20 0.37
CCR1 P32246 1/20 0.37
CCR2 P41597 1/20 0.37
CCR4 P51679 1/20 0.37
PPARG P37231 2/20 0.36
DDR1 Q08345 1/20 0.35
CNR1 P21554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16619066 0.99 HTR6 (0.39) HTR6RORCMPOSLC20A2SLC20A1
SCHEMBL16626740 0.95 HTR6 (0.43) HTR6CNR2CNR1
Hydrochloric Acid SCHEMBL16618768 0.94 HTR6 (0.43) HTR6CNR2CNR1
SCHEMBL16626721 0.92 HTR6 (0.40) HTR6RORCMPOSLC20A2SLC20A1
Hydrochloric Acid SCHEMBL16619421 0.91 RORC (0.40) HTR6RORCMPOSLC20A2SLC20A1
SCHEMBL16626502 0.90 HTR6 (0.42) HTR6SLC20A2SLC20A1PPARG
Hydrochloric Acid SCHEMBL16618540 0.90 HTR6 (0.42) HTR6SLC20A2SLC20A1PPARG
SCHEMBL16626500 0.89 RORC (0.40) HTR6RORCSLC20A2SLC20A1CCR1
SCHEMBL16626516 0.88 RORC (0.43) HTR6RORCSLC20A2SLC20A1CNR2
Hydrochloric Acid SCHEMBL16618896 0.88 RORC (0.40) HTR6RORCSLC20A2SLC20A1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885RORC 1067/4885MPO 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.